Finance

Lists
AUTL:NASDAQ
Autolus Therapeutics PLC
$2.03
-3.79%
(-0.080) 1D
$2.07
+1.97% (+0.040)
After hours
Closed: Sep 9, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AUTL...
Open
$2.10
High
$2.10
Low
$2.02
Mkt. cap
540.31M
Avg. vol.
2.87M
Volume
0.00
52-wk high
$2.58
52-wk low
$1.18
EPS
-$1.05
Beta
2.10
Shares outstanding
266.16M
No. of employees
753
Open
$2.10
High
$2.10
Low
$2.02
Mkt. cap
540.31M
Avg. vol.
2.87M
Volume
0.00
52-wk high
$2.58
52-wk low
$1.18
EPS
-$1.05
Beta
2.10
Shares outstanding
266.16M
No. of employees
753
News stories
From web sources and news partners
About Autolus Therapeutics PLC
CEOChristian Itin
Employees753
Founded2014
Headquarters-
SectorBiotechnology
Websiteautolus.com
Analyst ratings
Based on 6 analysts giving stock ratings to AUTL in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AUTL in the last 3 months.
Highest
Current $2.03
$10.00 (+392.61%)
Average
$8.16 (+301.97%)
Lowest
$5.00 (+146.31%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matt Phipps
William Blair
Buy
Maintained
-
-
09/09/2026
Unknown Analyst
Wells Fargo
Buy
Reiterated
$5.00
+146.3%
08/12/2026
Rajan Sharma
Goldman Sachs
Buy
Reiterated
$5.80
+185.7%
08/11/2026
Gil Blum
Needham
Buy
Reiterated
$10.00
+392.6%
08/11/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$10.00
+392.6%
08/11/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$10.00
+392.6%
06/10/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
$5.40
+166%
05/15/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.15 / -$0.19
+19.64%beat
Revenue / Est. (USD)
45.69M / 40.15M
+13.79%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
21.19M
24.29M
26.22M
45.69M
Cost of goods sold
56.54M
54.29M
45.78M
48.37M
Cost of revenue
56.54M
54.29M
45.78M
48.37M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
36.28M
42.12M
39.95M
41.16M
Operating expense
36.28M
42.12M
39.95M
41.16M
Total operating expenses
92.82M
96.41M
85.73M
89.53M
Operating income
-71.62M
-72.12M
-59.51M
-43.84M
Other non operating income
84.00K
-11.66M
100.00K
15.35M
EBT including unusual items
-78.59M
-91.52M
-70.74M
-38.65M
EBT excluding unusual items
-78.59M
-91.17M
-70.74M
-38.65M
Income tax expense
532.00K
-1.18M
863.00K
465.00K
Effective tax rate
-0.68%
1.29%
-1.22%
-1.20%
Other operating expenses
-
-
-
-
Net income
-79.12M
-90.33M
-71.60M
-39.11M
Net profit margin
-373.30%
-371.90%
-273.09%
-85.60%
Earnings per share
-0.30
-0.34
-0.27
-0.15
Interest and investment income
4.38M
3.23M
2.47M
1.88M
Interest expense
-10.52M
-11.01M
-11.12M
-12.50M
Net interest expenses
-6.14M
-7.78M
-8.66M
-10.62M
Depreciation and amortization charges
-
-
-
-
EBITDA
-69.08M
-69.49M
-56.81M
-41.19M
Gain or loss from assets sale
-
11.00K
2.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps